Ozempic, Mounjaro and Hair Loss

Do Ozempic and Mounjaro cause hair loss?

Ozempic contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors. Both medicines improve blood-glucose control and commonly reduce appetite and body weight. The newly reported study found a small increase in hair-loss diagnoses among treated adults with type 2 diabetes when compared with patients using two other established classes of glucose-lowering medicine.

Because the analysis was observational, it cannot separate the effects of the drugs from every difference between patient groups. Diabetes itself, thyroid disease, iron deficiency, hormonal changes, acute illness and other medicines can contribute to hair loss. Researchers therefore describe the result as a safety signal that warrants further study, not definitive evidence of direct follicle toxicity.

Why might hair shedding occur during GLP-1-based treatment?

One plausible explanation is telogen effluvium, a usually temporary form of diffuse hair shedding that can follow rapid weight loss, illness, surgery or major nutritional change. These stressors shift more hairs than usual into the resting phase of the growth cycle, with noticeable shedding often appearing weeks or months later. This mechanism does not require a medicine to act directly on the hair follicle.

Nausea, vomiting or prolonged appetite suppression may also make it harder to consume adequate protein, iron and other nutrients. However, patients should not assume that every episode is caused by weight loss or diet. Pattern hair loss, autoimmune alopecia, thyroid disorders, anemia and scalp disease require different evaluation and treatment.

What should patients do if they notice hair loss?

A clinician can review when the shedding began, how quickly weight changed, whether the hair loss is diffuse or patchy, and whether other symptoms are present. Depending on the clinical history, evaluation may include a medication review, scalp examination and tests for conditions such as anemia, iron deficiency or thyroid dysfunction.

Stopping treatment suddenly may worsen blood-glucose control and remove established metabolic benefits. Patients and clinicians can instead discuss nutrition, the pace of weight loss, dose tolerability and alternative treatments when appropriate. Prompt assessment is especially important for patchy loss, scalp inflammation, scarring, eyebrow loss or shedding accompanied by significant fatigue or other systemic symptoms.